Tcm Advisors, LLC Abb Vie Inc. Transaction History

Tcm Advisors, LLC

$888 Million
Q3 2024

A detailed history of Tcm Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Tcm Advisors, LLC holds 7,300 shares of ABBV stock, worth $1.28 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

7,300

Previous 7,600 3.95%

Holding current value

$1.28 Million

Previous $1.3 Million 10.59%

% of portfolio

0.16%

Previous 1.14%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$163.84 - $199.33 $49,152 - $59,799	-300 Reduced 3.95%	7,300 $1.44 Million
Q2 2024 Aug 13, 2024	SELL	$154.79 - $180.76 $170,269 - $198,836	-1,100 Reduced 12.64%	7,600 $1.3 Million
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $95,892 - $109,260	-600 Reduced 6.45%	8,700 $1.58 Million
Q4 2023 Feb 12, 2024	BUY	$137.6 - $154.97 $55,040 - $61,988	400 Added 4.49%	9,300 $1.44 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $26,718 - $30,930	-200 Reduced 2.2%	8,900 $1.33 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $13,251 - $16,490	-100 Reduced 1.09%	9,100 $1.23 Million
Q4 2022 Feb 09, 2023	SELL	$138.31 - $165.87 $55,324 - $66,348	-400 Reduced 4.17%	9,200 $1.49 Million
Q3 2022 Nov 09, 2022	SELL	$134.21 - $153.93 $26,842 - $30,786	-200 Reduced 2.04%	9,600 $1.29 Million
Q1 2022 May 11, 2022	SELL	$131.98 - $163.75 $158,376 - $196,500	-1,200 Reduced 10.91%	9,800 $1.59 Million
Q4 2021 Apr 29, 2022	BUY	$107.43 - $135.93 $1.18 Million - $1.5 Million	11,000 New	11,000 $1.5 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tcm Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tcm Advisors, LLC with notifications on news.

Account